Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (81-90 of 190) with videos related to

Pageof 19
Sort By:
Rheumatology and Therapy|December 17, 2021
Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid ArthritisRoy Fleischmann, Kyle Hayes, Sung-Woo Ahn, et al.
Arthritis Research & Therapy|November 5, 2015
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDsVibeke Strand, Joel Kremer, Gene Wallenstein, et al.
Arthritis and Rheumatism|March 2, 2011
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one yearJoel M Kremer, Ricardo Blanco, Marek Brzosko, et al.
Arthritis and Rheumatism|November 22, 2012
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized studyMichael E Weinblatt, Michael Schiff, Robert Valente, et al.
Annals of the Rheumatic Diseases|August 22, 2013
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trialMichael Schiff, Michael E Weinblatt, Robert Valente, et al.
Annals of the Rheumatic Diseases|December 18, 2013
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisJonathan Kay, Roy Fleischmann, Edward Keystone, et al.
European Journal of Rheumatology|June 8, 2021
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studiesMark C Genovese, Patrick Durez, Roy Fleischmann, et al.
The Journal of Rheumatology|March 23, 2002
Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenacDaniel E Furst, Karen S Kolba, Roy Fleischmann, et al.
British Journal of Clinical Pharmacology|December 10, 2015
Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosusJennifer Witcher, Roy Fleischmann, Vishala L Chindalore, et al.
Rheumatology (Oxford, England)|February 2, 2023
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritisGerd R Burmester, Vibeke Strand, Alan J Kivitz, et al.
Pageof 19

Showing results (81-90 of 190) with videos related to

Sort By:
Pageof 19
Rheumatology and Therapy|December 17, 2021
Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid ArthritisRoy Fleischmann, Kyle Hayes, Sung-Woo Ahn, et al.
Arthritis Research & Therapy|November 5, 2015
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDsVibeke Strand, Joel Kremer, Gene Wallenstein, et al.
Arthritis and Rheumatism|March 2, 2011
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one yearJoel M Kremer, Ricardo Blanco, Marek Brzosko, et al.
Arthritis and Rheumatism|November 22, 2012
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized studyMichael E Weinblatt, Michael Schiff, Robert Valente, et al.
Annals of the Rheumatic Diseases|August 22, 2013
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trialMichael Schiff, Michael E Weinblatt, Robert Valente, et al.
Annals of the Rheumatic Diseases|December 18, 2013
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisJonathan Kay, Roy Fleischmann, Edward Keystone, et al.
European Journal of Rheumatology|June 8, 2021
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studiesMark C Genovese, Patrick Durez, Roy Fleischmann, et al.
The Journal of Rheumatology|March 23, 2002
Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenacDaniel E Furst, Karen S Kolba, Roy Fleischmann, et al.
British Journal of Clinical Pharmacology|December 10, 2015
Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosusJennifer Witcher, Roy Fleischmann, Vishala L Chindalore, et al.
Rheumatology (Oxford, England)|February 2, 2023
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritisGerd R Burmester, Vibeke Strand, Alan J Kivitz, et al.
Pageof 19